We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

39 hedge funds and large institutions have $14.3M invested in Titan Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 1

515% more call options, than puts

Call options by funds: $1.91M | Put options by funds: $311K

440% more capital invested

Capital invested by funds: $2.65M → $14.3M (+$11.7M)

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

160% more funds holding

Funds holding: 15 → 39 (+24)

Holders
39
Holders Change
+24
Holders Change %
+160%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
7
Reduced
2
Closed
1
Calls
$1.91M
Puts
$311K
Net Calls
+$1.6M
Net Calls Change
+$312K

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$2.88M
2
State Street
State Street
Massachusetts
+$1.77M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.58M
4
Northern Trust
Northern Trust
Illinois
+$980K
5
BIT
BlackRock Institutional Trust
California
+$767K

Top Sellers

Rank Fund Capital Flow
1
SIM
Spark Investment Management
New York
-$298K
2
DADC
D.A. Davidson & Co
Montana
-$170K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$26K
Name Holding Trade Value Shares
Change 		Change in
Stake
NFA
26
Nationwide Fund Advisors
Ohio
$66K +$63.9K +3 New
SIM
27
Spark Investment Management
New York
$60K -$298K -14 -82%
AIG
28
American International Group
New York
$59.2K +$63.9K +3 New
DADC
29
D.A. Davidson & Co
Montana
$54K -$170K -8 -73%
BA
30
BlackRock Advisors
Delaware
$37K +$42.6K +2 New
Morgan Stanley
31
Morgan Stanley
New York
$35K +$21.3K +1 +100%
Creative Planning
32
Creative Planning
Kansas
$27K +$21.3K +1 New
Wells Fargo
33
Wells Fargo
California
$16K – – –
Deutsche Bank
34
Deutsche Bank
Germany
$15K +$21.3K +1 New
BCM
35
Blume Capital Management
California
$14K – – –
Simplex Trading
36
Simplex Trading
Illinois
$11K +$21.3K +1 New
AIM
37
Arcadia Investment Management
Michigan
$10K – – –
Citigroup
38
Citigroup
New York
$10K +$21.3K +1 New
TRCT
39
Tower Research Capital (TRC)
New York
$10K +$21.3K +1 New
AIM
40
Acrospire Investment Management
Illinois
$7K – – –
AIS
41
Accurate Investment Solutions
Pennsylvania
$5K – – –
IWMPD
42
Integrated Wealth Management (Palm Desert)
California
$5K – – –
MFS
43
MSI Financial Services
Massachusetts
$5K – – –
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$4.07K – – –
BlackRock
45
BlackRock
New York
$4K – – –
KF
46
Krilogy Financial
Missouri
$4K – – –
BFEC
47
Benjamin F. Edwards & Company
Missouri
$3K – – –
DOA
48
D'Orazio & Associates
Virginia
$3K – – –
HNB
49
Huntington National Bank
Ohio
$3K – – –
UBS Group
50
UBS Group
Switzerland
$3K – – –
1
2
3

TTNP Hedge Fund Activity: Q2 2016 in Review

39 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2016, worth a combined $14.3M — up 440% from $2.65M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TTNP positions and 1 closed out — a net gain of 24 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $2.88M. The largest seller was Spark Investment Management, cutting an estimated $298K.

  • 39 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2016, up from 15 in Q1 2016.
  • Funds reported $14.3M of Titan Pharmaceuticals stock for Q2 2016, up 440% quarter-over-quarter.
  • 25 funds opened new Titan Pharmaceuticals positions in Q2 2016 and 1 closed out, a net change of +24 holders.
  • The largest Titan Pharmaceuticals buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $2.88M added.
  • The largest Titan Pharmaceuticals seller in Q2 2016 was Spark Investment Management, an estimated $298K sold.

Based on aggregated 13F filings for Q2 2016.